+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The beta2-adrenergic receptor agonists in the treatment of chronic obstructive pulmonary disease



The beta2-adrenergic receptor agonists in the treatment of chronic obstructive pulmonary disease



Przeglad Lekarski 62(7): 724-728



Chronic obstructive pulmonary disease (COPD) is considered one of the most common chronic diseases in the world. It is characterized by the progressive reduction of the respiratory parameters, relatively low effectiveness of recommended treatment as well as serious prognosis especially in the group of patients with advanced disease. The beta2-adrenergic receptor agonists are first-line therapeutics in the treatment of COPD patients. Due to their diverse pharmacokinetic characteristic beta2-mimetics are recommended both for regular or "rescue" treatment to prevent or to restrain dyspnea symptoms. This paper evaluates main differences between the mechanism of action and pharmacokinetic profile of the key beta2-mimetics, discusses consequences of those diversities for their the clinical application and potential side effects.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050577270

Download citation: RISBibTeXText

PMID: 16463710


Related references

Dual dopamine D2 receptor and beta2-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease: the pre-clinical rationale. Respiratory Medicine 97 Suppl A: S3-S7, 2003

Beta2-adrenergic receptor polymorphisms as a determinant of preferential bronchodilator responses to β2-agonist and anticholinergic agents in Japanese patients with chronic obstructive pulmonary disease. Pharmacogenetics and Genomics 21(11): 687-693, 2012

Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 1(): Cd010139-Cd010139, 2015

Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews (): Cd010177-Cd010177, 2014

The place of long-acting beta 2 adrenergic agonists in the treatment of asthma and chronic obstructive pulmonary disease. Nederlands Tijdschrift Voor Geneeskunde 143(14): 764-764, 1999

Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. Pulmonary Pharmacology & Therapeutics 30: 44-50, 2015

Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine 87(6): 319-328, 2008

Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 1(3): 200-206, 2005

The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology 110(6 Suppl): S298-S303, 2002

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews (): Cd001104-Cd001104, 2006

Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease. Drugs 60(2): 307-320, 2000

Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. International Journal of Chronic Obstructive Pulmonary Disease 3(4): 521-529, 2009

Combination long-acting beta2-agonists and inhaled corticosteroids in chronic obstructive pulmonary disease. Clinical Medicine 4(5): 470; Author Reply 470-470; Author Reply 470, 2004

Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease. Bioorganic & Medicinal Chemistry Letters 18(4): 1284-1287, 2008

Beta2 agonists and anticholinergics. Inhalation therapy in acute deterioriation of asthma and chronic obstructive pulmonary disease. Ugeskrift for Laeger 158(42): 5957-5962, 1996